Streamlining Medicare Aimovig Prior Authorization

Navigating Medicare Aimovig prior authorization for erenumab, a CGRP receptor antagonist for migraine prevention, requires precise understanding of both Original Medicare and Part D plan requirements. Klivira streamlines this complex process.

For revenue cycle directors and prior authorization coordinators, managing prior authorizations for specialized medications like Aimovig (erenumab) under Medicare presents unique challenges. This page outlines the specific considerations for obtaining approval for Aimovig, focusing on Medicare's distinct PA mechanisms and how Klivira's platform can optimize these workflows.

Aimovig (Erenumab): A CGRP Receptor Antagonist for Migraine Prevention

Aimovig (erenumab) is a CGRP receptor antagonist indicated for the preventive treatment of chronic migraine and episodic migraine. As a specialty biologic, it often requires prior authorization to ensure medical necessity and adherence to payer-specific utilization management criteria. Step therapy through generic preventive therapies is common before approval for CGRP inhibitors.

Medicare Prior Authorization Context for Aimovig

Prior authorization for Aimovig under Medicare depends on the specific benefit coverage. For members with Original Medicare, prior authorization scope is generally limited. However, most Aimovig prescriptions fall under Medicare Part D, which is administered by private plans. These Part D plans apply their own CMS-approved formularies, step-therapy protocols, and quantity limits, making PA a critical step for coverage.

Submission Channels and Policy Access for Medicare PA

For any limited prior authorization required under Traditional Medicare (Part A/B), submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. MACs such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas handle these processes. Klivira's platform employs MAC-aware routing to ensure submissions reach the correct contractor. For Aimovig under Part D, submissions are directed to the specific commercial insurer operating the Part D plan. Coverage policies are guided by CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) published by MACs, which Klivira integrates for NCD/LCD-aware policy logic.

Navigating Part D Formularies and Step Therapy for Aimovig

Medicare Part D plans often implement utilization management strategies for high-cost specialty drugs like Aimovig. This commonly includes step therapy requirements, where patients must first try and fail specific lower-cost alternatives before Aimovig is covered. Plans may also impose quantity limits or specific medical necessity criteria. Klivira helps providers navigate these complex formulary requirements by integrating with payer policy libraries and facilitating ePA submissions.

Klivira's Role in Optimizing Aimovig Prior Authorization for Medicare

Klivira's platform streamlines the prior authorization process for Aimovig under Medicare by automating submission workflows. For Traditional Medicare, our system routes PA requests through the correct MAC jurisdiction. For Medicare Part D, Klivira connects directly with commercial Part D plans, facilitating ePA submissions that adhere to specific plan formularies and step-therapy protocols. This reduces manual effort, accelerates turnaround times, and minimizes administrative burden for your team.

Frequently asked questions

Does Original Medicare (Part A/B) typically require prior authorization for Aimovig?

Original Medicare's scope for prior authorization is limited. Aimovig (erenumab) is a pharmacy benefit drug, meaning its coverage and associated prior authorization requirements primarily fall under Medicare Part D plans, not Original Medicare Part A or B.

How do Medicare Part D plans determine coverage for Aimovig?

Medicare Part D plans, operated by private insurers, determine Aimovig coverage based on their CMS-approved formularies. These formularies outline which drugs are covered, at what tier, and often include utilization management strategies like prior authorization, step therapy, and quantity limits.

What are common prior authorization requirements for Aimovig under Medicare Part D?

Common requirements for Aimovig under Medicare Part D often include documentation of a migraine diagnosis (chronic or episodic), a history of prior failed preventive therapies (step therapy), and confirmation that the patient meets specific medical necessity criteria outlined in the plan's policy. Klivira helps compile and submit this documentation efficiently.

How does Klivira assist with Aimovig prior authorizations for Medicare members?

Klivira automates the prior authorization process for Aimovig by integrating with Medicare Part D plans. Our platform routes ePA submissions, applies NCD/LCD-aware policy logic, and helps manage step-therapy requirements, reducing manual tasks and accelerating approval cycles for your team.

Where can I find specific coverage policies for Aimovig under Medicare?

Specific coverage policies for Aimovig under Medicare Part D are found in the formularies and medical policies of individual Part D plans. For any limited Traditional Medicare PA, National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) published by MACs provide guidance. Klivira integrates these policy sources to inform PA workflows.